Skip to search formSkip to main contentSkip to account menu

Anti-FGFR2 Monoclonal Antibody FPA144

Known as: FPA144 
A glycoengineered, humanized monoclonal antibody directed against the fibroblast growth factor receptor type 2b (FGFR2b), with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
PURPOSE To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b… 
2019
2019
91 Background: GC with FGFR2b overexpression or FGFR2 amplification is associated with a poor prognosis. Bemarituzumab (bema… 
2018
2018
TPS4135Background: FGFR2b overexpression and FGFR2 gene amplification occurs in approximately 10% of patients with gastric cancer… 
2017
2017
4067Background: FGFR2b-overexpressing gastric cancer is characterized by poor prognosis. FPA144, a humanized monoclonal IgG1… 
2016
2016
2502Background: FGFR2b-overexpressing gastric cancer is a distinct setting with poor prognosis. FPA144, a humanized monoclonal… 
2016
2016
140 Background: FPA144 is a humanized monoclonal IgG1 antibody directed against the 2b Isoform of thefibroblast growth factor… 
2014
2014
A subset of patients with gastric cancer have an amplification of the receptor tyrosine kinase fibroblast growth factor receptor… 
2014
2014
e15074 Background: Amplification of the Fibroblast Growth Factor Receptor 2 (FGFR2) gene is reported in ~5% of gastric cancer…